D&D Pharmatech touts positive Phase II results for DD01 in MASH

17 June 2025

South Korea’s clinical-stage biotech D&D Pharmatech (Kosdaq: 347850) saw its share leap as much as 30% as it revealed “remarkably positive” results on its metabolic dysfunction-associated steatohepatitis (MASH) candidate.

The company announced positive results from DD01-DN-02 study, an ongoing 48-week Phase II trial designed to evaluate the efficacy and safety of DD01 (a once-weekly dual GLP1/glucagon receptor agonist) in 67 overweight/obese subjects with MASH.

DD01 treatment was initiated with two weeks of dosing at 20mg, followed by the 40mg once-weekly maintenance dose.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology